Genitourinary Cancer News

We have known for more than 50 years that immunotherapy is active against noninvasive bladder cancer, dating from the paradigm-altering work of Donald Lamm, MD, FACS, Alvaro Morales, MD, the EORTC investigators and others.

Erdafitinib induced a high rate of objective tumor response in patients with locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations, according to results of a single-arm phase 2 study published in The New England Journal of Medicine.

Healio.com and HemOnc Today provide a compilation of seven important updates in immuno-oncology from the past month.

Non-Latino white adolescents and young adults who are cancer survivors have a lower risk for subsequent death compared with survivors of other races and ethnicities, according to research published in JNCI Cancer Spectrum.

Nivolumab demonstrated limited activity among patients with untreated brain metastases from clear cell renal cell carcinoma who experienced progression after vascular endothelial growth factor receptor-directed therapy, according to results of a phase 2 study published in Journal of Clinical Oncology.

The ability to harness the human immune system and use it to fight cancer remains a significant area of focused research and is likely to remain so until the next great advancement occurs. Meanwhile, companies like Fate Therapeutics are going all-in on their own versions of immune effector cell therapies to treat cancer.

Consensus molecular subtype classification demonstrated potential clinical utility as an independent prognostic factor for patients with metastatic colorectal cancer who receive first-line therapy, according to results of a prospective phase 3 trial published in Journal of Clinical Oncology.

The American Urological Association has released a new guideline on the diagnosis and treatment of early-stage testicular cancer.

Targeted therapies appeared associated with modest improvements in OS compared with nontargeted therapies among elderly patients with metastatic renal cell carcinoma, according to results of a retrospective study published in JAMA Network Open.

The FDA approved bevacizumab-bvzr for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.